Prostate Cancer Vaccines: What’s In The Pipeline?
Executive Summary
The sector still attracts the attention of clinical investigators and the pharmaceutical industry, despite disappointing results from another clinical-stage candidate.
You may also be interested in...
PROSPECTs Futile For Bavarian Nordic's Prostvac Cancer Vaccine
The Phase III PROSPECT study's data monitoring committee decides against continuing after interim analysis. The fall-out could hit Bavarian Nordic’s CV301 too.
Argos And Agenus Trials Pile On Fresh Cancer Vaccine Disappointments
Argos mum on details surrounding Phase III failure of rocapuldencel-T in kidney cancer, while Agenus distances itself from failed Phase II glioblastoma study of Prophage G-200 as an investigator-sponsored trial with a challenging design.
Debt-laden Valeant Sells Its Assets, More Divestments Likely
Troubled Valeant has started the new year by announcing the sale of some $2.1bn in assets to get funds to hone down its operations and to start easing its debt burden amid allegations of unethical practices.